MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtho.2021.10.022

Медицинская библиотека · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021

Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.

Kosari Farhad, Disselhorst Maria, Yin Jun, Peikert Tobias, Udell Julia, Johnson Sarah, Smadbeck James, Murphy Stephen, McCune Alexa, Karagouga Giannoula, Desai Aakash, Schaefer-Klein Janet, Borad Mitesh J, Cheville John, Vasmatzis George, Baas Paul, Mansfield Aaron S

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

The favorable outcomes with immunotherapy for mesothelioma were somewhat unexpected because this tumor has a low tumor mutation burden which has been associated with benefit in other cancers. Because chromosomal rearrangements are common in mesothelioma and have neoantigenic potential, we sought to determine whether they are associated with survival in patients treated with immunotherapy.

METHODS

Pleural biopsies of mesothelioma after at least one line of therapy were obtained from patients (n = 44) before treatment with nivolumab alone (NCT29908324) or in combination with ipilimumab (NCT30660511). RNA and whole-genome sequencing were performed to identify the junctions resulting from chromosomal rearrangements and antigen processing and presentation gene set expression. Associations with overall survival (OS) were estimated using Cox models. An OS cutoff of 1.5 years was used to distinguish patients with and without durable benefit for use in receiving operating characteristic curves.

RESULTS

Although tumor junction burdens were not predictive of OS, we identified significant interactions between the junction burdens and multiple antigen processing and presentation gene sets. The "regulation of antigen processing and presentation of peptide antigen" gene set revealed an interaction with tumor junction burden and was predictive of OS. This interaction also predicted 1.5-year or greater survival with an area under the receiving operating characteristic curve of 0.83. This interaction was not predictive of survival in a separate cohort of patients with mesothelioma who did not receive immune checkpoint inhibitors.

CONCLUSIONS

Analysis of structural variants and antigen presentation gene set expression may facilitate patient selection for immune checkpoint inhibitors.

Для цитирования: Kosari Farhad, Disselhorst Maria, Yin Jun, Peikert Tobias, Udell Julia, Johnson Sarah, Smadbeck James, Murphy Stephen, McCune Alexa, Karagouga Giannoula, Desai Aakash, Schaefer-Klein Janet, Borad Mitesh J, Cheville John, Vasmatzis George, Baas Paul, Mansfield Aaron S. Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021. DOI: 10.1016/j.jtho.2021.10.022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.